Randomized Study to Evaluate the Use of High-Dose Therapy as Part of Primary Treatment for “Aggressive” LymphomaUlrich Kaiser, K. Havemann, Dieter K. Hossfeld et al.|Journal of Clinical Oncology|2002Cited by 139
An open-label, Phase I study of cediranib (RECENTIN™) in patients with acute myeloid leukemiaWalter Fiedler, Hubert Serve, Rolf M. Mesters et al.|Leukemia Research|2009Cited by 42
Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHLKarin Hohloch, Michael Pfreundschuh, Carsten Zwick et al.|SpringerPlus|2014Cited by 10
An Open, Phase I Study of Cediranib in Patients with Acute Myeloid Leukemia (AML).Walter Fiedler, Hubert Serve, Rolf M. Mesters et al.|Blood|2007Cited by 1